| Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures R Vander Velde, N Yoon, V Marusyk, A Durmaz, A Dhawan, ... Nature communications 11 (1), 2393, 2020 | 84 | 2020 |
| Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature A Kaznatcheev, R Vander Velde, JG Scott, D Basanta British journal of cancer 116 (6), 785-792, 2017 | 60 | 2017 |
| Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations D Miroshnychenko, E Baratchart, MC Ferrall-Fairbanks, RV Velde, ... Nature Ecology & Evolution 5 (3), 379-391, 2021 | 52 | 2021 |
| Optimal therapy scheduling based on a pair of collaterally sensitive drugs N Yoon, R Vander Velde, A Marusyk, JG Scott Bulletin of mathematical biology 80, 1776-1809, 2018 | 39 | 2018 |
| Roadmap on plasticity and epigenetics in cancer J Foo, D Basanta, RC Rockne, C Strelez, C Shah, K Ghaffarian, ... Physical biology 19 (3), 031501, 2022 | 12 | 2022 |
| Antifragile therapy J West, B Desai, M Strobl, L Pierik, RV Velde, C Armagost, R Miles, ... BioRxiv, 2020.10. 08.331678, 2020 | 8 | 2020 |
| The neutral, hydrophobic isoleucine at position I521 in the extracellular S4 domain of hERG contributes to channel gating equilibrium Y Dou, SJ Goodchild, RV Velde, Y Wu, D Fedida American Journal of Physiology-Cell Physiology 305 (4), C468-C478, 2013 | 8 | 2013 |
| Understanding the evolutionary games in NSCLC microenvironment R Bhattacharya, RV Velde, V Marusyk, B Desai, A Kaznatcheev, ... bioRxiv, 2020.11. 30.404350, 2020 | 7 | 2020 |
| Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm R Vander Velde, S Shaffer, A Marusyk Trends in cancer 8 (6), 456-466, 2022 | 5 | 2022 |
| The impact of tumor stromal architecture on therapy response and clinical progression PM Altrock, N Yoon, JA Bull, H Wu, J Ruiz-Ramírez, D Miroshnychenko, ... bioRxiv, 451047, 2018 | 5 | 2018 |
| Clonal differences underlie variable responses to sequential and prolonged treatment DL Schaff, AJ Fasse, PE White, RJ Vander Velde, SM Shaffer Cell Systems, 2024 | 1 | 2024 |
| Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and promotes tumor … B Desai, M Robertson-Tessi, R Vander Velde, T Miti, S Yarlagadda, ... CANCER RESEARCH 84 (3), 2024 | | 2024 |
| Abstract A016: Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and … B Desai, M Robertson-Tessi, RV Velde, T Miti, S Yarlagadda, R Shah, ... Cancer Research 84 (3_Supplement_2), A016-A016, 2024 | | 2024 |
| Abstract A026: EGF/EGFR signaling in priming for resistance to BRAF/MEK inhibitors in melanoma RJ Vander Velde, SM Shaffer Cancer Research 84 (3_Supplement_2), A026-A026, 2024 | | 2024 |
| Abstract A013: Cell-extrinsic mechanisms of accelerated therapy resistance mediated by altered pharmacokinetics P Kumar, RV Velde, V Turati, A Marusyk Cancer Research 84 (3_Supplement_2), A013-A013, 2024 | | 2024 |
| Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer J West, B Desai, M Strobl, L Pierik, RV Velde, M Robertson-Tessi, ... Cancer Research 83 (7_Supplement), 847-847, 2023 | | 2023 |
| Abstract B016: Selection and reprogramming contribute to the evolution of targeted therapy resistance RV Velde, S Shaffer Cancer Research 82 (10_Supplement), B016-B016, 2022 | | 2022 |
| Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer R Vander Velde University of South Florida, 2021 | | 2021 |
| Resistance to ALK targeting therapies as a gradual Darwinian adaptation to inhibitor specific selective pressures R Vander Velde, N Yoon, V Marusyk, A Dhawan, O Balynska, B Desai, ... bioRxiv, 504837, 2018 | | 2018 |
| Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia A Kaznatcheev, DR Grimes, RV Velde, V Cannataro, E Baratchart, ... bioRxiv, 211151, 2017 | | 2017 |
